These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38472556)

  • 1. Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study.
    Luo C; Luo S; Wusimanjiang W; Wang Z; Liu P; Wang B; Yuan D; Lin H; Xu A; Deng N; Wu K; Zhu X; Xu P; Chen J; Huang B
    Clin Transl Oncol; 2024 Jul; 26(7):1759-1767. PubMed ID: 38472556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Cisplatin-Based Chemotherapy Followed by Selective Bladder Preservation Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder: Post Hoc Analysis of Two Prospective Studies.
    Cho SW; Lim SH; Kwon GY; Kim CK; Park W; Pyo H; Chung JH; Song W; Sung HH; Jeong BC; Park SH
    Cancer Res Treat; 2024 Jul; 56(3):893-897. PubMed ID: 38374699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
    Funt SA; Lattanzi M; Whiting K; Al-Ahmadie H; Quinlan C; Teo MY; Lee CH; Aggen D; Zimmerman D; McHugh D; Apollo A; Durdin TD; Truong H; Kamradt J; Khalil M; Lash B; Ostrovnaya I; McCoy AS; Hettich G; Regazzi A; Jihad M; Ratna N; Boswell A; Francese K; Yang Y; Folefac E; Herr HW; Donat SM; Pietzak E; Cha EK; Donahue TF; Goh AC; Huang WC; Bajorin DF; Iyer G; Bochner BH; Balar AV; Mortazavi A; Rosenberg JE
    J Clin Oncol; 2022 Apr; 40(12):1312-1322. PubMed ID: 35089812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    Rose TL; Harrison MR; Deal AM; Ramalingam S; Whang YE; Brower B; Dunn M; Osterman CK; Heiling HM; Bjurlin MA; Smith AB; Nielsen ME; Tan HJ; Wallen E; Woods ME; George D; Zhang T; Drier A; Kim WY; Milowsky MI
    J Clin Oncol; 2021 Oct; 39(28):3140-3148. PubMed ID: 34428076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
    Okabe K; Shindo T; Maehana T; Nishiyama N; Hashimoto K; Itoh N; Takahashi A; Taguchi K; Tachiki H; Tanaka T; Masumori N
    Jpn J Clin Oncol; 2018 Oct; 48(10):934-941. PubMed ID: 30169681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disitamab Vedotin Alone or in Combination With Immune Checkpoint Inhibitors in Bladder-Sparing Treatment of Muscle-Invasive Bladder Cancer: A Real-World Study.
    Wang A; Chen M; Li D; Shi J; Tang W; Zhang Z; Ren S
    Clin Genitourin Cancer; 2024 Jun; 22(3):102085. PubMed ID: 38636170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
    Murasawa H; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Iwabuchi I; Ogasawara M; Kawaguchi T
    Int J Clin Oncol; 2017 Feb; 22(1):159-165. PubMed ID: 27534866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Galsky MD; Daneshmand S; Izadmehr S; Gonzalez-Kozlova E; Chan KG; Lewis S; Achkar BE; Dorff TB; Cetnar JP; Neil BO; D'Souza A; Mamtani R; Kyriakopoulos C; Jun T; Gogerly-Moragoda M; Brody R; Xie H; Nie K; Kelly G; Horowitz A; Kinoshita Y; Ellis E; Nose Y; Ioannou G; Cabal R; Del Valle DM; Haines GK; Wang L; Mouw KW; Samstein RM; Mehrazin R; Bhardwaj N; Yu M; Zhao Q; Kim-Schulze S; Sebra R; Zhu J; Gnjatic S; Sfakianos J; Pal SK
    Nat Med; 2023 Nov; 29(11):2825-2834. PubMed ID: 37783966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
    Lee KCE; Mui WH; Chan W; Wong CSF; Chu SKP
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1170. PubMed ID: 32721111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
    Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
    Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
    Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.
    Xu C; Zou W; Zhang L; Xu R; Li Y; Feng Y; Zhao R; Wang Y; Liu X; Wang J
    Front Immunol; 2023; 14():1162580. PubMed ID: 37283762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.
    Iyer G; Balar AV; Milowsky MI; Bochner BH; Dalbagni G; Donat SM; Herr HW; Huang WC; Taneja SS; Woods M; Ostrovnaya I; Al-Ahmadie H; Arcila ME; Riches JC; Meier A; Bourque C; Shady M; Won H; Rose TL; Kim WY; Kania BE; Boyd ME; Cipolla CK; Regazzi AM; Delbeau D; McCoy AS; Vargas HA; Berger MF; Solit DB; Rosenberg JE; Bajorin DF
    J Clin Oncol; 2018 Jul; 36(19):1949-1956. PubMed ID: 29742009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
    Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y
    Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
    Meleis L; Moore R; Inman BA; Harrison MR
    J Oncol Pharm Pract; 2020 Mar; 26(2):330-337. PubMed ID: 31081469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.